GB0327840D0 - Organic compounds - Google Patents

Organic compounds

Info

Publication number
GB0327840D0
GB0327840D0 GBGB0327840.5A GB0327840A GB0327840D0 GB 0327840 D0 GB0327840 D0 GB 0327840D0 GB 0327840 A GB0327840 A GB 0327840A GB 0327840 D0 GB0327840 D0 GB 0327840D0
Authority
GB
United Kingdom
Prior art keywords
organic compounds
compounds
organic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0327840.5A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Priority to GBGB0327840.5A priority Critical patent/GB0327840D0/en
Publication of GB0327840D0 publication Critical patent/GB0327840D0/en
Priority to EP04803369A priority patent/EP1819361A2/en
Priority to PCT/EP2004/013587 priority patent/WO2005053661A2/en
Priority to KR1020067010547A priority patent/KR20060122877A/ko
Priority to US10/581,069 priority patent/US20070117833A1/en
Priority to CA002546738A priority patent/CA2546738A1/en
Priority to RU2006123312/15A priority patent/RU2006123312A/ru
Priority to BRPI0417146-2A priority patent/BRPI0417146A/pt
Priority to CNA2004800355130A priority patent/CN1886157A/zh
Priority to JP2006541869A priority patent/JP2007512381A/ja
Priority to AU2004294282A priority patent/AU2004294282B2/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
GBGB0327840.5A 2003-12-01 2003-12-01 Organic compounds Ceased GB0327840D0 (en)

Priority Applications (11)

Application Number Priority Date Filing Date Title
GBGB0327840.5A GB0327840D0 (en) 2003-12-01 2003-12-01 Organic compounds
AU2004294282A AU2004294282B2 (en) 2003-12-01 2004-11-30 Pharmaceutical combinations
US10/581,069 US20070117833A1 (en) 2003-12-01 2004-11-30 Pharmaceutical compositions
PCT/EP2004/013587 WO2005053661A2 (en) 2003-12-01 2004-11-30 Pharmaceutical combinations
KR1020067010547A KR20060122877A (ko) 2003-12-01 2004-11-30 제약 조합물
EP04803369A EP1819361A2 (en) 2003-12-01 2004-11-30 Pharmaceutical combinations
CA002546738A CA2546738A1 (en) 2003-12-01 2004-11-30 Pharmaceutical combinations
RU2006123312/15A RU2006123312A (ru) 2003-12-01 2004-11-30 Фармацевтические композиции
BRPI0417146-2A BRPI0417146A (pt) 2003-12-01 2004-11-30 combinações farmacêuticas
CNA2004800355130A CN1886157A (zh) 2003-12-01 2004-11-30 药物组合
JP2006541869A JP2007512381A (ja) 2003-12-01 2004-11-30 医薬的組み合わせ

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0327840.5A GB0327840D0 (en) 2003-12-01 2003-12-01 Organic compounds

Publications (1)

Publication Number Publication Date
GB0327840D0 true GB0327840D0 (en) 2003-12-31

Family

ID=29798110

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0327840.5A Ceased GB0327840D0 (en) 2003-12-01 2003-12-01 Organic compounds

Country Status (11)

Country Link
US (1) US20070117833A1 (https=)
EP (1) EP1819361A2 (https=)
JP (1) JP2007512381A (https=)
KR (1) KR20060122877A (https=)
CN (1) CN1886157A (https=)
AU (1) AU2004294282B2 (https=)
BR (1) BRPI0417146A (https=)
CA (1) CA2546738A1 (https=)
GB (1) GB0327840D0 (https=)
RU (1) RU2006123312A (https=)
WO (1) WO2005053661A2 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4547911B2 (ja) 2002-02-01 2010-09-22 アリアド・ファーマシューティカルズ・インコーポレイテッド リン含有化合物およびその用途
WO2006053754A1 (en) * 2004-11-19 2006-05-26 Novartis Ag COMBINATIONS OF ANTI-ATHEROSCLEROTIC PEPTIDES AND AN mTOR INHIBITING AGENT AND THEIR METHODS OF USE
CA2629714A1 (en) * 2005-11-14 2007-05-24 Ariad Gene Therapeutics, Inc. Administration of an mtor inhibitor to treat patients with cancer
AU2007204410A1 (en) * 2006-01-12 2007-07-19 Novartis Ag Combination of mTOR inhibitor and antipolate compound
EP1880723A1 (en) * 2006-07-14 2008-01-23 Novartis AG Combination of mTOR inhibitor and antifolate compound
LT1983984T (lt) * 2006-02-02 2018-06-11 Novartis Ag Tuberozinės sklerozės gydymas
US20090023768A1 (en) * 2006-02-24 2009-01-22 Novartis Ag Rapamycin derivatives for treating neuroblastoma
CN103330694A (zh) 2006-11-14 2013-10-02 阿里亚德医药股份有限公司 口服制剂

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9221220D0 (en) * 1992-10-09 1992-11-25 Sandoz Ag Organic componds
US5258389A (en) * 1992-11-09 1993-11-02 Merck & Co., Inc. O-aryl, O-alkyl, O-alkenyl and O-alkynylrapamycin derivatives
EP0833828B1 (en) * 1995-06-09 2002-11-20 Novartis AG Rapamycin derivatives
GB0123025D0 (en) * 2001-09-25 2001-11-14 Eirx Therapeutics Ltd Apoptosis
TW200306826A (en) * 2002-01-10 2003-12-01 Novartis Ag Drug delivery systems for the prevention and treatment of vascular diseases
JP4547911B2 (ja) * 2002-02-01 2010-09-22 アリアド・ファーマシューティカルズ・インコーポレイテッド リン含有化合物およびその用途
AU2003247483A1 (en) * 2002-05-30 2003-12-31 The Children's Hospital Of Philadelphia Methods for treatment of acute lymphocytic leukemia
JP2006517969A (ja) * 2003-02-14 2006-08-03 コンビナトアールエックス インコーポレーティッド 免疫炎症性障害の治療のための組み合わせ療法

Also Published As

Publication number Publication date
WO2005053661A2 (en) 2005-06-16
WO2005053661A3 (en) 2005-12-29
AU2004294282A1 (en) 2005-06-16
CN1886157A (zh) 2006-12-27
RU2006123312A (ru) 2008-01-20
KR20060122877A (ko) 2006-11-30
US20070117833A1 (en) 2007-05-24
JP2007512381A (ja) 2007-05-17
BRPI0417146A (pt) 2007-03-06
EP1819361A2 (en) 2007-08-22
AU2004294282B2 (en) 2009-05-07
CA2546738A1 (en) 2005-06-16

Similar Documents

Publication Publication Date Title
GB0301259D0 (en) Organic compounds
GB0308335D0 (en) Organic compounds
GB0325603D0 (en) Organic compounds
GB0306715D0 (en) Organic compounds
GB0302876D0 (en) Organic compounds
GB0327840D0 (en) Organic compounds
GB0322612D0 (en) Organic compounds
GB0325175D0 (en) Organic compounds
GB0300095D0 (en) Organic compounds
GB0302748D0 (en) Organic compounds
GB0301938D0 (en) Organic compounds
GB0301471D0 (en) Organic compounds
GB0308853D0 (en) Organic compounds
GB0303506D0 (en) Organic compounds
GB0302991D0 (en) Organic compounds
GB0306070D0 (en) Organic compounds
GB0306071D0 (en) Organic compounds
GB0300910D0 (en) Organic compounds
GB0302749D0 (en) Organic compounds
GB0330031D0 (en) Organic compounds
GB0300021D0 (en) Organic compounds
GB0328442D0 (en) Organic compounds
GB0300590D0 (en) Organic compounds
GB0303323D0 (en) Organic compounds
GB0328045D0 (en) Organic compounds

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)